CN100473388C - 一种从蝼蛄中提取的抗肿瘤有效部位及制备方法 - Google Patents
一种从蝼蛄中提取的抗肿瘤有效部位及制备方法 Download PDFInfo
- Publication number
- CN100473388C CN100473388C CNB2004100251627A CN200410025162A CN100473388C CN 100473388 C CN100473388 C CN 100473388C CN B2004100251627 A CNB2004100251627 A CN B2004100251627A CN 200410025162 A CN200410025162 A CN 200410025162A CN 100473388 C CN100473388 C CN 100473388C
- Authority
- CN
- China
- Prior art keywords
- gryllotalpa
- extract
- extracting
- tumor
- effective site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000605 extraction Methods 0.000 title claims description 5
- 241001243087 Gryllotalpidae Species 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 241000241125 Gryllotalpa gryllotalpa Species 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 241001243091 Gryllotalpa Species 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 239000003208 petroleum Substances 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 15
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 5
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 239000003960 organic solvent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000006491 bone marrow cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000003495 polar organic solvent Substances 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000785585 Gryllotalpa africana Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100251627A CN100473388C (zh) | 2004-06-15 | 2004-06-15 | 一种从蝼蛄中提取的抗肿瘤有效部位及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100251627A CN100473388C (zh) | 2004-06-15 | 2004-06-15 | 一种从蝼蛄中提取的抗肿瘤有效部位及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1582970A CN1582970A (zh) | 2005-02-23 |
CN100473388C true CN100473388C (zh) | 2009-04-01 |
Family
ID=34601170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100251627A Expired - Fee Related CN100473388C (zh) | 2004-06-15 | 2004-06-15 | 一种从蝼蛄中提取的抗肿瘤有效部位及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100473388C (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101716192B (zh) * | 2010-01-07 | 2012-03-21 | 福建农林大学 | 一种利用高速逆流色谱分离中药蝼蛄药效学物质的方法 |
CN102293785B (zh) * | 2011-08-29 | 2012-12-12 | 河南科技大学 | 一种昆虫或节肢动物次生代谢物的提取方法 |
CN102526591B (zh) * | 2012-01-16 | 2014-03-26 | 殷永洲 | 一种治疗白血病的中草药组合物 |
CN109549956B (zh) * | 2017-09-25 | 2022-07-12 | 上海医药工业研究院 | 蝼蛄提取物在制备治疗脑胶质瘤药物中的应用 |
CN109568347B (zh) * | 2017-09-25 | 2022-07-12 | 上海医药工业研究院 | 一种蝼蛄提取物及其提取方法 |
CN109589341B (zh) * | 2017-09-29 | 2022-07-12 | 上海医药工业研究院 | 蝼蛄提取物及其制备方法 |
CN109589340B (zh) * | 2017-09-29 | 2022-07-12 | 上海医药工业研究院 | 蝼蛄提取物在制备治疗三阴乳腺癌药物中的应用 |
-
2004
- 2004-06-15 CN CNB2004100251627A patent/CN100473388C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1582970A (zh) | 2005-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101031298B (zh) | 具有镇痛作用的药物 | |
CN103880910A (zh) | 一种环黄芪醇的制备方法及其用途 | |
CN113262258B (zh) | 白木香花提取物及其药物与其制备方法和其应用 | |
CN102670720A (zh) | 海南地不容总生物碱提取物及其制备方法 | |
CN101850032B (zh) | 一种具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
CN100473388C (zh) | 一种从蝼蛄中提取的抗肿瘤有效部位及制备方法 | |
CN102370695B (zh) | 一种青龙衣活性提取物及其制备方法和用途 | |
CN102068535A (zh) | 乙醇回流提取的枳实或枳壳总黄酮提取物及其用途 | |
CN102731276B (zh) | 具有抗肿瘤活性的二萜化合物及其制备方法与应用 | |
CN101677989B (zh) | 一种防治缺血性脑卒中的药物组合物及其制备方法 | |
CN102875615B (zh) | 大麻药苷a和大麻药总皂苷的提取方法及其应用 | |
CN102228547B (zh) | 一种中药组合物在制备治疗胰腺炎和/或胆囊炎药物中的应用 | |
TWI610676B (zh) | 神經細胞死抑制劑、抗阿茲海默症劑、抗腦機能減退劑、具有抗阿茲海默症作用或抗腦機能減退作用的醫藥品及神經細胞死抑制劑的製造方法 | |
CN101433575B (zh) | 一种乌桕种子提取物及其制备方法 | |
CN101411779B (zh) | 一种治疗肝癌的中药有效部位组合物及其制备方法 | |
CN101948453B (zh) | Neo-克罗烷型二萜化合物及其应用 | |
CN102302615A (zh) | 一种祖师麻叶有效部位群、其制备方法、药物组合物和应用 | |
CN101912485B (zh) | 一种具有抗炎镇痛作用的药物组合物及其制备方法和用途 | |
CN104435293B (zh) | 异型南五味子总三萜乙醇提取物在制备抗关节炎药物中的应用 | |
CN102204956B (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN101019824B (zh) | 一种含有丹参丹酚酸a的口服药物组合物的制备方法 | |
CN104523795A (zh) | 鹿茸糖肽组合物在制备耐缺氧药品及保健食品中的应用 | |
CN104257955A (zh) | 一种含有东北天南星的抗肝癌中药混合物及其生产方法 | |
CN1968694B (zh) | 具有镇痛作用的药物组合物 | |
CN103735591B (zh) | 一种抗消化性溃疡的组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO Free format text: FORMER OWNER: SHANGHAI AOLONG TECHNOLOGY DEVELOPMENT CO., LTD.; APPLICANT Effective date: 20060825 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060825 Address after: 201203 92 Zhangjiang Road, Shanghai, Pudong New Area Applicant after: Shanghai Pharmaceutical Technology Development Co.,Ltd. Address before: 200433 No. 122-2, National Road, Shanghai Applicant before: Aolong Science and Technology Development Co.,Ltd. Shanghai Co-applicant before: Hou Jian Co-applicant before: Kong Deyun Co-applicant before: Dai Qiming |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Free format text: FORMER OWNER: AOLONG SCIENCE + TECHNOLOGY DEVELOPMENT CO., LTD. OF SHANGHAI Effective date: 20130122 Owner name: AOLONG SCIENCE + TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: SHANGHAI MEDICINE SCIENCE + TECHNOLOGY DEVELOPING CO., LTD. Effective date: 20130122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wu Tong Inventor after: Kong Deyun Inventor after: Yang Peiming Inventor after: Dai Qiming Inventor before: Huang Junqin Inventor before: Wu Jianwen |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 200086 HONGKOU, SHANGHAI Free format text: CORRECT: INVENTOR; FROM: HUANG JUNQIN WU JIANWEN TO: WU TONG KONG DEYUN YANG PEIMING DAI QIMING Free format text: CORRECT: ADDRESS; FROM: 200086 HONGKOU, SHANGHAI TO: 200040 JING'AN, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130122 Address after: 200040 Beijing West Road, Shanghai, No. 1320, No. Patentee after: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Address before: 200086 Shanghai city Hongkou District Zhoujiazui road 981 Lane 8, room 1001 Patentee before: Aolong Science and Technology Development Co.,Ltd. Shanghai Effective date of registration: 20130122 Address after: 200086 Shanghai city Hongkou District Zhoujiazui road 981 Lane 8, room 1001 Patentee after: Aolong Science and Technology Development Co.,Ltd. Shanghai Address before: 201203 Pudong New Area Zhangjiang Road, Shanghai, No. 92 Patentee before: Shanghai Pharmaceutical Technology Development Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090401 Termination date: 20180615 |
|
CF01 | Termination of patent right due to non-payment of annual fee |